I-01 Martina Liebich Modelling of Dexamethasone in Paediatric Leukaemia Patients using a Population Pharmacokinetic Approach Wednesday 10:30-12:00 |
I-02 Klaus Lindauer Model Simplification Wednesday 10:30-12:00 |
I-03 Dan Liu Application of Global Sensitivity Analysis Methods to Determine the most Influential Parameters of a Minimal PBPK Model of Quinidine Wednesday 10:30-12:00 |
I-04 Rocio Lledo PK/PD modelling of an anti-FcRn mAb to optimise FIM design - translation from cyno to human Wednesday 10:30-12:00 |
I-05 Florence Loingeville Using Hamiltonian Monte-Carlo to design longitudinal count studies accounting for parameter and model uncertainties Wednesday 10:30-12:00 |
I-06 Amelia Deitchman Tigecycline-Tetracycline Combination Modeling against Pseudomonas aeruginosa: Application of the General Pharmacodynamic Interaction Term in Various Interaction Models Wednesday 10:30-12:00 |
I-07 Dominik Lott Tolerance modeling: effects of the selective S1P1 receptor modulator ponesimod on heart rate Wednesday 10:30-12:00 |
I-08 Rubin Lubomirov Population pharmacokinetic-based interspecies allometric scaling and prediction of first-in-human (FIH) pharmacokinetics of a new anticancer agent Wednesday 10:30-12:00 |
I-09 Inga Ludwig Correlative analysis of response to treatment and biomarker levels in a setting with a time-to-event efficacy outcome and sparse biomarker data Wednesday 10:30-12:00 |
I-10 John C Lukas Order in patch absorption rates? Wednesday 10:30-12:00 |
I-11 Sreenath M Krishnan Influence of the number of tumor size measurements on model-derived tumor size metrics and prediction of survival Wednesday 10:30-12:00 |
I-12 Lei Ma Dupilumab dose selection for a phase 3 study in asthma patients: pharmacokinetic/pharmacodynamic (PK/PD) modelling and clinical trial simulation Wednesday 10:30-12:00 |
I-13 Vincent Madelain Modeling viral kinetics predicts a rapid establishment of the cytotoxic immune response targeting distinct infected cell compartments in SIV controller macaques (ANRS SIC study) Wednesday 10:30-12:00 |
I-14 Paolo Magni Execution of complex Bayesian workflows with the DDMoRe Interoperability Framework: a case study in the diabetes area Wednesday 10:30-12:00 |
I-15 Corinna Maier Robust parameter estimation for dynamical systems from outlier-corrupted data Wednesday 10:30-12:00 |
I-16 Victor Mangas-Sanjuan Semi-mechanistic Pharmacodynamic model of complex receptor-hormone dynamics Wednesday 10:30-12:00 |
I-17 Ben Margetts Modelling Cytomegalovirus Growth Kinetics in Immunocompromised Children Wednesday 10:30-12:00 |
I-18 Dimitris Maris Asymptotic Analysis on a TMDD model: Control of the process Wednesday 10:30-12:00 |
I-19 Emma Martin Using mixed effects modelling improves detection of drug-gene interactions in mouse trials Wednesday 10:30-12:00 |
I-20 Paolo Mazzei Translational model-based approach to assist the dose-range selection of an antibody-drug conjugate entering Phase I Wednesday 10:30-12:00 |
I-21 Nicola Melillo Multiscale mechanistic models in Systems Pharmacology: development of a model describing Atorvastatin pharmacokinetics through integration of metabolic network in Physiologically Based Pharmacokinetic models. Wednesday 10:30-12:00 |
I-22 Sandrine Micallef Evaluation of tumor kinetics metrics as early endpoint to support decision making in early drug development Wednesday 10:30-12:00 |
I-23 Joske Millecam A new approach in pediatric drug design: the development of a pediatric pig model. Part II: The maturation of hepatic cytochrome P450 enzymes using enzyme activity and proteomics Wednesday 10:30-12:00 |
I-24 Jonathan Mochel One Health: Translational and Reverse Translational Modeling of Inflammatory Bowel Disease using an advanced Boolean Network Wednesday 10:30-12:00 |
I-25 Daniel Moj Application of a physiologically-based pharmacokinetic and pharmacodynamic (PBPK/PD) model of the histone deacetylase (HDAC) inhibitor vorinostat to improve dosing regimens in adults Wednesday 10:30-12:00 |
I-26 Tadakatsu Nakamura Population Pharmacokinetic Analysis of Compound A and Its Metabolite in Healthy Subjects and Patients with Diabetic Nephropathy Wednesday 10:30-12:00 |
I-27 Srividya Neelakantan Population Pharmacokinetic Analysis of Recombinant Factor VIII Fc Fusion Protein in Subjects with Severe Hemophilia A Across All Ages Wednesday 10:30-12:00 |
I-28 Asuka Suzuki A Bayesian approach for population pharmacokinetic modeling of alcohol in Japanese Subjects Wednesday 10:30-12:00 |
I-29 Thu Thuy Nguyen Population pharmacodynamic model of bronchodilator response to salbutamol in wheezy preschool children Wednesday 10:30-12:00 |
I-30 Rikard Nordgren Calling C functions from NONMEM Wednesday 10:30-12:00 |
I-31 Ana Novakovic A longitudinal model linking absolute lymphocyte count (ALC) and volume of T2 lesions to expanded disability status scale (EDSS) in patients with relapsing-remitting multiple sclerosis (RRMS) Wednesday 10:30-12:00 |
I-32 Kayode Ogungbenro Sparse sampling design for characterizing individual PK of recombinant factor VIII fusion protein (rFVIIIFc) in prophylactic treatment of Hemophilia A Wednesday 10:30-12:00 |
I-33 Boram Ohk Population Pharmacokinetics of Tacrolimus in Healhty Korean Subjects:role of CYP3A5 genotype and metabolite Wednesday 10:30-12:00 |
I-34 Olafuyi Olusola The Use of Physiologically Based Pharmacokinetic Modelling in Assessing Drug–drug Interactions Associated with Antimalarial Treatment in Paediatrics Co-infected with Tuberculosis: A Case Study with Lumefantrine and Rifampicin. Wednesday 10:30-12:00 |
I-35 Sean Oosterholt PKPD modelling of MYCN-inhibition in vitro and in vivo in a mouse model of neuroblastoma Wednesday 10:30-12:00 |
I-36 - - Investigation of Bayesian inference in predicting tissue concentrations using RStan Wednesday 10:30-12:00 |
I-37 Maria Panselina Dose-saturable model for amoxicillin used to predict probability of response in normal and obese pediatrics Wednesday 10:30-12:00 |
I-38 Sang-In Park Population pharmacokinetic analysis of evogliptin in subjects with varying degrees of renal function Wednesday 10:30-12:00 |
I-39 Zinnia Parra-Guillen Exploring the impact of study design on unperturbed tumour growth inhibition modelling Wednesday 10:30-12:00 |
I-40 Christophe Passot In-depth assessment of the influence of anti-drug antibodies on adalimumab pharmacokinetics and concentration-effect relationship in rheumatoid arthritis Wednesday 10:30-12:00 |
I-41 Dimple Patel Informing modeling and clinical trial simulation using the real world data: data content, quality and availability assessment Wednesday 10:30-12:00 |
I-42 Dimitrios Patsatzis Construction and evaluation of "global" Micahelis-Menten reduced models Wednesday 10:30-12:00 |
I-43 Sophie Peigné How to handle non-linearity in absorption: a case study in oncology Wednesday 10:30-12:00 |
I-44 Nathalie Perdaems Multi-species translational PK/PD modelling in type 2 diabetes Wednesday 10:30-12:00 |
I-45 Belén Pérez Solans Modelling tumour growth and progression free survival of breast cancer patients treated with neoadjuvant therapy Wednesday 10:30-12:00 |
I-46 Jonás Samuel Pérez-Blanco Population PK and exposure-response analysis of sleep parameters for JNJ-42847922, a novel Orexin 2 receptor antagonist Wednesday 10:30-12:00 |
I-47 Carlos Perez-Ruixo Identifying lack of adherence to antipsychotic treatment using plasma concentrations measurements Wednesday 10:30-12:00 |
I-48 Chiara Piana A model-based approach to extrapolate drug-drug interactions from rats to humans Wednesday 10:30-12:00 |
I-49 Philippe Pierrillas Application of Model-Based Adaptive Optimal Design to determine a recommended dosing regimen for combination therapy in oncology Wednesday 10:30-12:00 |
I-50 Nikhil Pillai Estimating Nonlinear Dynamic Systems in Pharmacology using Chaos Synchronization Wednesday 10:30-12:00 |
I-51 Italo Poggesi A Shiny App for the Probability of Technical Success of a New Molecular Entity in the Preclinical to Clinical Translational Phase Wednesday 10:30-12:00 |
I-52 Sebastian Polak Physiologically based pharmacokinetic model (PBPK) for the halofantrine cardiac effect prediction – proof of concept study towards the system for the antimalarial drugs cardiac safety assessment. Wednesday 10:30-12:00 |
I-53 Manuel Prado-Velasco PBPK versus PK modeling of Tacrolimus drug in patients with renal transplant as knowledge engines for personalized posology software: PhysPK® development and preliminary results Wednesday 10:30-12:00 |
I-54 Tim Preijers Population pharmacokinetic analysis of perioperative factor IX dosing in hemophilia B Wednesday 10:30-12:00 |
I-55 Angelica Quartino Crenezumab exposure-response across Alzheimer’s Disease endpoints supports a higher dose for Phase 3 Wednesday 10:30-12:00 |
I-56 Christian Hove Claussen PharmTeX: a LaTeX-based open-source platform for automated reporting workflow Wednesday 10:30-12:00 |
I-57 Theo Reijmers Population PK Modeling of Dapivirine released from Vaginal Rings Wednesday 10:30-12:00 |
I-58 Didier Renard Label extension for canakinumab in Adult Onset Still’s Disease (AOSD) – Extrapolation from pediatrics to adults Wednesday 10:30-12:00 |
I-59 Christer Rimmler Development of a PBPK model to predict the pharmacokinetics of cefuroxime during surgery Wednesday 10:30-12:00 |
I-60 Christelle Rodrigues Population pharmacokinetics of the sustained-release granule formulation of valproic acid in epileptic children Wednesday 10:30-12:00 |
I-61 Amin Rostami Predicting diclofenac systemic and synovial fluid concentrations after dermal application using the Multi-Phase Multi-Layer MechDermA PBPK model Wednesday 10:30-12:00 |
I-62 Hauke Ruehs Exposure-response analysis of vilaprisan describing uterine fibroid size by population PK/PD modelling Wednesday 10:30-12:00 |
I-63 Leire Ruiz Cerdá Modeling of Interferon effector pathway after viral infection Wednesday 10:30-12:00 |
I-64 Alberto Russu Dose-conversion factors for risperidone and paliperidone formulations based on steady-state PK similarity Wednesday 10:30-12:00 |
I-65 Sunae Ryu Population pharmacokinetic model of propranolol and its metabolite reflecting the first-pass effect in patients with hepatic impairment Wednesday 10:30-12:00 |
I-66 Muhammad Waqas Sadiq A model-based comparison of absorption pharmacokinetics for a selective glucocorticoid receptor modulator administered with different inhalation devices Wednesday 10:30-12:00 |
I-68 Mark Sale Application of global search methods for parameter estimation in models with poorly defined objective function surfaces Wednesday 10:30-12:00 |
I-69 Franziska Schädeli Stark Assessing the adequacy of a minimal PK sampling schedule for individual dose adjustment decisions in a proof of mechanism (PoM) study in a special population Wednesday 10:30-12:00 |
I-70 Stein Schalkwijk Placental Transfer of Darunavir and Simulation of Fetal Exposure Wednesday 10:30-12:00 |